Clinical trial · no report yet · Phase 2

TELESTO trial: what clinicians have said so far

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

NCT00940602 ↗
Completed
Novartis Pharmaceuticals
Focused size, estimated: 1–150 verified statements

We haven't built an HCP commentary report on TELESTO (deferasirox in transfusion-dependent low- to intermediate-1-risk myelodysplastic syndromes) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on TELESTO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
3 YouTube videos
3 podcast episodes
3 posts on X

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload
Phase: Phase 2
Status: Completed
Conditions: Myelodysplastic Syndromes
Interventions: Deferasirox; Placebo
Arms: Deferasirox · Experimental
Placebo · Placebo comparator
Enrollment: 225
Primary outcomes: Event-free Survival
Sponsor: Novartis Pharmaceuticals
Start: Mar 22, 2010
Primary completion: Feb 27, 2018
Results posted: Yes
Registry record: NCT00940602 · updated Nov 23, 2020

Publications

linked from the registry

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24. PubMed 32203980

Get this report

Focused

Report, built on orderBuilt within 24 hours of confirming your order: $750

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md